dc.contributorMontes Romero, Félix Ramón
dc.contributorMolano-González, Nicolas
dc.creatorPérez Coronado, Juan David
dc.date.accessioned2022-02-28T15:33:22Z
dc.date.accessioned2022-09-22T14:50:58Z
dc.date.available2022-02-28T15:33:22Z
dc.date.available2022-09-22T14:50:58Z
dc.date.created2022-02-28T15:33:22Z
dc.identifierhttps://repository.urosario.edu.co/handle/10336/33782
dc.identifierhttps://doi.org/10.48713/10336_33782
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3442691
dc.description.abstractBackground: Transcatheter Aortic Valve Implantation (TAVI) is an alternative for the management of aortic stenosis and has undergone rapid perioperative management evolution. International centers have reported that as the experience evolves, the results improve. The aim is to describe the evolution of the anesthetic and perioperative management of TAVI at the Fundación Cardioinfantil between January 2014 and June 2020. Methods: Observational, retrospective descriptive study. Evolution of preoperative, intraoperative and postoperative variables will be described. Results: 206 procedures were performed. Over time, a change in patients with high surgical to intermediate risk was found. At the beginning the procedures were performed in the operation room, then an hybrid room was implemented. Initially all were performed under general anesthesia and later 90% under sedation. Use of central venous catheter (77%) or a pulmonary artery catheter (23%) was changed to 89% only with an arterial catheter. Use of transesophageal echocardiography changed from 100% to 0%. There was a decrease in the duration of the procedure from 175 minutes to 56 minutes. In the postoperative, decrease in hospitalization from 7 to 3 days was observed. The complications that showed a decrease were: mechanical ventilation (31% to 0%), atrial fibrillation (8% to 0%), need for a pacemaker (8% to 0%), major vascular complications (38% to 0%) and 30-day mortality (46% to 4%). Conclusions: The evolution in perioperative management for TAVI in our center was characterized by the selection of lower risk patients, implementation of the hybrid room, change from general anesthesia to sedation, less invasive intraoperative monitoring, reduction of procedure and hospitalization time, less complications and decreased in 30-day mortality.
dc.languagespa
dc.publisherUniversidad del Rosario
dc.publisherEspecialización en Anestesia Cardiotorácica
dc.publisherEscuela de Medicina y Ciencias de la Salud
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto Completo)
dc.rightsEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.
dc.rightsAtribución-CompartirIgual 2.5 Colombia
dc.rightsAtribución 2.5 Colombia
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.source[1]. Buchanan JW, Anderson JH, White RI. The 1st balloon valvuloplasty: an historical note. J Vet Intern Med.2002;16(1):116–7.
dc.source[2]. Cribier A, T Savin. Percutaneous transluminal valvuloplasty of acquired aortic stenosis in elderly patients: an alternative to valve replacement? Lancet.1986;1 (8472):63–7.
dc.source[3]. Andersen HR, Knudsen LL, Hasenkam JM. Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs. Eur Heart J. 1992;13(5):704–8.
dc.source[4]. Figulla HR, M. Franz and A. Lauten, The history of Transcatheter Aortic Valve Implantation (TAVI)—A personal view over 25years of development. Cardiovascular Revascularization Medicine 2019;21(3):398-403
dc.source[5]. Figulla HR, Eitge N, Ferrari M. Konstruktion und in vitro Testung einer perkutan implantierbaren Aortenklappe. Z Kardiol. 1996;85(2):161.
dc.source[6] Cribier A, Eltchaninoff H. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: First human case description. Circulation. 2002;106(24):3006– 8.
dc.source[7]. Webb JG, Chandavimol M. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation. 2006;113(6):842–50.
dc.source[8]. Lichtenstein SV, Cheung A, Ye J. Transapical transcatheter aortic valve implantation in humans: initial clinical experience. Circulation. 2006;114(6):591–6.
dc.source[9]. Cribier A, Eltchaninoff H,Tron C. Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis. J Am Coll Cardiol. 2004;43(4):698–703.
dc.source[10]. Grube E, Laborde JC, Zickmann B, Gerckens U, Felderhoff T, Sauren B, et al. First report on a human percutaneous transluminal implantation of a self-expanding valve prosthesis for interventional treatment of aortic valve stenosis. Catheter Cardiovasc Interv. 2005;66(4):465–9.
dc.source[11]. Leon MB, Smith CR, Mack M, Miller C. Transcatheter Aortic-Valve Implantation for
Aortic Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med. 2010;363:1597–1607
dc.source[12]. Leon MB, Smith CR, Mack MJ. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016;374:1609–1620.
dc.source[13]. Reardon MJ, Van Mieghem NM. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017;376:1321–1331
dc.source[14]. Smith CR, Leon MB, Mack MJ, Miller C, Moses JW, Svensson LG, et al. Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients. N Engl J Med. 2011;364:2187–2198.
dc.source[15]. Nishimura RA, Otto CM. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Vol. 135, Circulation. 2017. 1159–1195.
dc.source[16]. Baumgartner H, Falk V, Bax JJ, De Bonis M. ESC Document Group; 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739-91
dc.source[17]. Gurvitch R, Tay EL, Wijesinghe N. Transcatheter aortic valve implantation: lessons from the learning curve of the first 270 high-risk patients. Catheter Cardiovasc Interv. 2011;78(7): 977-984.
dc.source[18]. Wang H, Zhang X. Advances in the Anesthetic Management of Transcatheter Aortic Valve Implantation. Journal of Cardiothoracic and Vascular Anesthesia. 2018;32: 1464-1467.
dc.source[19]. Melidi E. Cardio-anesthesiology considerations for the trans-catheter aortic valve implantation (TAVI) procedure. Hellenic Society of Cardiology. 2016:57:401-406.
dc.source[20]. Webb JG, Doshi D, Mack MJ. A randomized evaluation of the SAPIEN XT transcatheter heart valve system in patients with aortic stenosis who are not candidates for surgery. JACC Cardiovasc Interv. 2015; 21:1797–806.
dc.source[21]. Leon MB, Smith CR. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016; 374: 1609–20.
dc.source[22]. Thourani VH, Kodali S. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: A propensity score analysis. Lancet. 2016; 387:2218–25.
dc.source[23]. Erez A, Segev A, Medvedofsky D, et al. Factors affecting survival in men versus women following transcatheter aortic valve implantation. Am J Cardiol 2014; 113:701–5.
dc.source[24]. Saia F, Marrozzini C, Moretti C. The role of percutaneous balloon aortic valvuloplasty as a bridge for transcatheter aortic valve implantation. EuroIntervention . 2011;7:723–9.
dc.source[25]. Snow TM, Ludman P, Banya W. Management of concomitant coronary artery disease in patients undergoing transcatheter aortic valve implantation: The United Kingdom TAVI Registry. Int J Cardiol . 2015;15: 253–60
dc.source[26]. Davidson L, Davidson CJ. TAVI mixed with acute kidney injury: A recipe for increased mortality. Catheter Cardiovasc Interv. 2015;85:448–9.
dc.source[27]. Hamm CW, Arsalan M, Mack MJ. The future of transcatheter aortic valve implantation. Eur Heart J. 2016;37:803-810.
dc.source[28]. Patel P. Anesthetic Evolution in Transcatheter Aortic Valve Replacement: Expert Perspectives From High-Volume Academic Centers in Europe and the United States. Journal of Cardiothoracic and Vascular Anesthesia. 2017: 31 : 777–790.
dc.source[29]. De Backer O, Arnous S. Recovery from anemia in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation-prevalence, predictors and clinical outcome. PLoS One. 2014;9(12):1-16.
dc.source[30]. Kowalski M, Deutsh C. Transcatheter aortic valve implantation at a high-volume center: the Bad Rothenfelde experience. Torakochirurgia Polska .2017; 14 (4): 215-224.
dc.source[31]. Guarracino F, Baldassarri R. The anesthetic management of transcatheter aortic valve implantation. Semin Cardiothorac Vasc Anesth. 2015;9:45–8
dc.source[32]. Holmes DR Jr, Mack MJ. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol. 2012;59:1200–54
dc.source[33]. Kaier K, Reinecke H, Schmoor C, Frankenstein L, Vach W, Hehn P, et al . Learning Curves Among All Patients Undergoing Transcatheter Aortic Valve Implantation in Germany: A Retrospective Observational Study. International Journal of Cardiology. 2017: 1-3
dc.source[34]. Arai T, Lefevre T. Evaluation of the learning curve for transcatheter aortic valve implantation via the transfemoral approach. International Journal of Cardiology. 2016 ;203: 491–497.
dc.source[35]. Lareyre F, Raffort J, Dommerc C, Habib Y, Bourton F,Mialhe C. A 7-Year Single-Center Experience of Transfemoral TAVI: Evolution of Surgical Activity and Impact on Vascular Outcome. Angiology.2017;69(6): 1-18.
dc.source[36]. Kappetein P, Stuart J. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document. The Journal of Thoracic and Cardiovascular Surgery. Clinical Guidelines. 2013; 145 (1):6-23.
dc.source[37]. Moat NE, Ludman P. Long-Term Outcomes After Transcatheter Aortic Valve Implantation in High-Risk Patients With Severe Aortic Stenosis. ACC. 2011;58(20): 2130-8.
dc.source[38]. Finkelstein A, Birati E. Transcatheter Aortic Valve implantation: a single-center experience of 300 cases. IMAJ .2013; 15 (10): 613–616.
dc.source[39]. Caorsi C, Baeza C. Implante valvular aórtico transarterial: experiencia en Chile. Rev Med Chile. 2013; 141: 7-14.
dc.source[40]. Dager A, Nuis R. Colombian Experience with Transcatheter Aortic Valve Implantation of Medtronic CoreValve. Tex Heart Inst J. 2012;39(3):351-8.
dc.source[41]. Schwartz A, Goulart M. Transcatheter Aortic Valve Replacement: The Experience of One Brazilian Health Care Center. Braz J Cardiovasc Surg.2018;33(1):1-7
dc.source[42]. De Brito F, Carvalho L. Outcomes and Predictors of Mortality After Transcatheter Aortic Valve Implantation: Results of the Brazilian Registry. Catheterization and Cardiovascular Interventions. 2015;85:153-162.
dc.source[43]. Nau G, Zaidel E, Echeverry D. Multicenter Experience of Transcatheter Aortic Valve Implantation Stratified by Risk in Latin American Centers. Revista Argentina de Cardiología. 2020;88:106-110.
dc.source[44]. World Medical Association. Revisión Declaración de Helsinki, 59a Asamblea General, Seúl Corea Octubre 2008.
dc.source[45]. Ministerio de Salud. Resolución número 8430 de 1993, (Octubre 4):1–1
dc.source[46]. Abdel-Wahab M, Landt M. 5-Year Outcomes After TAVR With Balloon-Expandable Versus Self-Expanding Valves: Results From the CHOICE Randomized Clinical Trial. JACC Cardiovasc Interv. 2020 May 11;13(9):1071-1082.
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectImplante Transcatéter de la Válvula Aórtica
dc.subjectEvolución
dc.subjectPerioperatorio
dc.subjectEstenosis aórtica
dc.subjectManejo anestésico
dc.subjectTAVI
dc.titleEvolución del manejo anestésico y perioperatorio en el implante transcatéter de la Válvula Aórtica en un Centro Cardiovascular Colombiano: experiencia de la Fundación Cardioinfantil
dc.typemasterThesis


Este ítem pertenece a la siguiente institución